分析胶质母细胞瘤患者血清中的自身抗体。

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-09-12 DOI:10.1080/1750743x.2024.2390350

Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu

{"title":"分析胶质母细胞瘤患者血清中的自身抗体。","authors":"Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu","doi":"10.1080/1750743x.2024.2390350","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"42 1","pages":"1-8"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Profiling of autoantibodies in the sera of glioblastoma patients.\",\"authors\":\"Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu\",\"doi\":\"10.1080/1750743x.2024.2390350\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\"42 1\",\"pages\":\"1-8\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743x.2024.2390350\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743x.2024.2390350","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在确定IV级胶质母细胞瘤患者血清中自身抗体蛋白的表达模式：我们通过Sengenics i-Ome®蛋白质阵列进行了高通量抗体分析，以确定差异表达的自身抗体：结果：抗COL4A3BP和抗HSP90AA1是胶质母细胞瘤血清中上调的自身抗体之一：结论：所选自身抗体为未来胶质母细胞瘤的发病机制提供了有希望的靶点。结论：所选的自身抗体为未来胶质母细胞瘤的发病机制提供了有希望的靶点，然而，要阐明胶质母细胞瘤患者的自身抗体特征还需要进一步的验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Profiling of autoantibodies in the sera of glioblastoma patients.

Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.